Conditioned medium (cm) (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
90 | Retinitis pigmentosa | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04315025 (ClinicalTrials.gov) | October 7, 2018 | 8/3/2020 | Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa | Safety Issues of Peribulbar Injection of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC);Biological: Conditioned Medium (CM) | PT. Prodia Stem Cell Indonesia | NULL | Completed | 18 Years | 65 Years | All | 18 | Phase 1;Phase 2 | Indonesia |